Investors Have Chance to Lead PepGen Securities Fraud Case with Faruqi & Faruqi, LLP

Overview of PepGen’s Situation



In recent months, PepGen Inc. (NASDAQ: PEPG) has found itself at the center of a significant legal investigation. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating claims against PepGen. Investors are encouraged to come forward if they suffered losses exceeding $50,000 between March 7, 2024, and March 3, 2025.

Legal Context



The reason behind this investigation is troubling. Allegations have surfaced that PepGen and its executives engaged in misleading practices that may have compromised the integrity of their securities offerings. The complaint suggests violations of federal securities laws due to false statements made by the Company regarding the effectiveness of its product, PGN-EDO51. This product is at the forefront of the company’s research efforts, particularly in connection with the ongoing CONNECT1 and CONNECT2 clinical studies.

Details of Allegations



The allegations specifically state that PepGen misrepresented the effectiveness and safety of PGN-EDO51. Notably, the CONNECT2 study faced scrutiny, as evidence suggested that it posed risks that were not appropriately disclosed to investors. Accordingly, analysts noted discrepancies in the clinical trial data released by the company, leading to a noticeable decline in stock value following such announcements.

For instance, after the release of clinical data on July 30, 2024, which purportedly indicated positive results, analysts pointed out that the information fell short of expectations. Following this realization, PepGen's stock price took a sharp hit, falling by over 32%, illustrating the direct impact of these alleged misleading claims. Over the following months, further negative disclosures about the FDA’s clinical hold on the CONNECT2 trial compounded the situation, driving the share price even lower. By March 2025, after announcing the temporary pause of the CONNECT2 study, PepGen’s stock continued to suffer, reinforcing concerns about the potential viability of its product.

Call to Action for Investors



With the deadline for seeking the position of lead plaintiff in the class action suit looming (set for August 11, 2025), this situation represents a critical juncture for impacted investors. By stepping forward, they could play a pivotal role in leading the lawsuit against PepGen. Faruqi & Faruqi partner, Josh Wilson, is actively inviting individuals who meet the criteria to discuss their legal options. Contact numbers, 877-247-4292 and 212-983-9330, have been provided for direct communication with the firm.

Conclusion and Further Steps



As this situation unfolds, it remains essential for investors aware of the situation or who have pertinent information to reach out to legal counsel. Faruqi & Faruqi is not only looking for potential class members but also any whistleblowers, previous employees, and shareholders who may possess additional insights into PepGen’s conduct.

Investors should not underestimate the value of their participation in this legal process, as the outcome could significantly influence their financial interests in PepGen. For more details regarding the class action suit, individuals can visit Faruqi & Faruqi’s website or continue to follow the firm’s updates on social media platforms such as LinkedIn and X.

By staying informed and proactive, investors can navigate this challenging landscape and potentially reclaim some of their losses through the unfolding litigation.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.